Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has issued an announcement.
CANbridge Pharmaceuticals Inc. has completed the subscription of new shares under a general mandate, raising gross proceeds of HKD100,461,767.12. This financial move is part of a strategic cooperation agreement with Baheal Zhihe, which will act as the exclusive marketing service provider for CANbridge’s products in designated regions. Additionally, the company has appointed Mr. Wang Tingwei as a non-executive director and a member of the Nomination Committee, further strengthening its corporate governance structure.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies for rare diseases and targeted cancers. The company operates primarily in the Greater China region, including Mainland China, Hong Kong, and Macau.
Average Trading Volume: 14,871,255
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.12B
Learn more about 1228 stock on TipRanks’ Stock Analysis page.